Company Presentation Company Presentation Other Presentations Lyell Presents New Ronde-Cel Clinical and Translational Data at ASH 2025 December 8, 2025 Lyell Strengthens Next-Generation CAR T-Cell Pipeline with Novel GCC-Targeted Product Candidate for Metastatic Colorectal Cancer November 10, 2025 New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma June 17, 2025 ASH 2024: First Phase 1 Clinical Results of IMPT-314, an Autologous Dual-Targeting CD19/CD20 CAR T-cell Product Candidate Enriched for Naïve and Central Memory T Cells, for the Treatment of Large B-cell Lymphoma December 9, 2024 SITC 2024: Utilizing Stim-R™ Technology to Reduce IrradiatedFeeder Cell Use in the Tumor Infiltrating Lymphocyte Culture Process November 9, 2024 SITC 2024: Multiomic Profiling of LYL119: Reprogramming ROR1CAR T cells With Reduced Exhaustion and Enhanced Memory Characteristics IsAssociated With Increased AP-1 and ReducedNR4A Binding November 8, 2024 SITC 2024: LYL797 Reprogrammed ROR-1 CAR T cells Demonstrate Limited Exhaustion, Maintenance of Stemness and Tumor Infiltration with Evidence of Tumor Lysis in Patients with Solid Tumors November 8, 2024 Lyell Strengthens Next Generation CAR TCell Pipeline October 24, 2024 Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1-targeted CAR-T Cell Product Candidate June 26, 2024 AACR 2024: Development of Tumor-restricted IL-12 With Antigen-dependent Expression and Localized IL-12 Activity April 9, 2024
Lyell Strengthens Next-Generation CAR T-Cell Pipeline with Novel GCC-Targeted Product Candidate for Metastatic Colorectal Cancer November 10, 2025
New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma June 17, 2025
ASH 2024: First Phase 1 Clinical Results of IMPT-314, an Autologous Dual-Targeting CD19/CD20 CAR T-cell Product Candidate Enriched for Naïve and Central Memory T Cells, for the Treatment of Large B-cell Lymphoma December 9, 2024
SITC 2024: Utilizing Stim-R™ Technology to Reduce IrradiatedFeeder Cell Use in the Tumor Infiltrating Lymphocyte Culture Process November 9, 2024
SITC 2024: Multiomic Profiling of LYL119: Reprogramming ROR1CAR T cells With Reduced Exhaustion and Enhanced Memory Characteristics IsAssociated With Increased AP-1 and ReducedNR4A Binding November 8, 2024
SITC 2024: LYL797 Reprogrammed ROR-1 CAR T cells Demonstrate Limited Exhaustion, Maintenance of Stemness and Tumor Infiltration with Evidence of Tumor Lysis in Patients with Solid Tumors November 8, 2024
Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1-targeted CAR-T Cell Product Candidate June 26, 2024
AACR 2024: Development of Tumor-restricted IL-12 With Antigen-dependent Expression and Localized IL-12 Activity April 9, 2024
